Reversal of cardiac transplant rejection without massive immunosuppression

Robert E. Michler, C. R. Smith, R. E. Drusin, D. S. Reison, T. J. Hickey, J. Lamb, K. Reemtsma, E. A. Rose

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Although cyclosporine has decreased the severity of acute cardiac transplant rejection, most centers have continued to use high-dose intravenous steroids to treat acute rejection. To minimize the morbidity of antirejection therapy, acute rejection episodes in 37 cardiac transplant recipients were treated prospectively with only a boost of oral prednisone. Cyclospoine was continued at the same maintenance dose while oral prednisone was increased to 100 mg/day for 3 days, then rapidly tapered over 1 week to the maintenance dose. Seventy-six of 85 acute rejection episodes (90%) showed histologic resolution of mycocyte necrosis on repeat biopsy. Three acute rejection episodes (3.5%) resolved only after 'rescue therapy' with intravenous steroid, and an additional three episodes (3.5%) required the combination of intravenous steroid and rabbit antithymocyte globulin to effect resolution. In addition, three acute rejection episodes (3.5%) resulted in graft loss. This was fatal in two patients and one patient underwent successful retransplantation. Oral steroid therapy alone is adequate therapy for most acute rejection episodes in cyclosporine-treated heart transplant recipients, and low infectious morbidity and mortality has been associated with this antirejection protocol.

Original languageEnglish (US)
JournalCirculation
Volume74
Issue number5 II MONOGR. 125
StatePublished - 1986
Externally publishedYes

Fingerprint

Graft Rejection
Immunosuppression
Steroids
Prednisone
Cyclosporine
Morbidity
Antilymphocyte Serum
Necrosis
Therapeutics
Rabbits
Transplants
Biopsy
Mortality
Transplant Recipients

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Michler, R. E., Smith, C. R., Drusin, R. E., Reison, D. S., Hickey, T. J., Lamb, J., ... Rose, E. A. (1986). Reversal of cardiac transplant rejection without massive immunosuppression. Circulation, 74(5 II MONOGR. 125).

Reversal of cardiac transplant rejection without massive immunosuppression. / Michler, Robert E.; Smith, C. R.; Drusin, R. E.; Reison, D. S.; Hickey, T. J.; Lamb, J.; Reemtsma, K.; Rose, E. A.

In: Circulation, Vol. 74, No. 5 II MONOGR. 125, 1986.

Research output: Contribution to journalArticle

Michler, RE, Smith, CR, Drusin, RE, Reison, DS, Hickey, TJ, Lamb, J, Reemtsma, K & Rose, EA 1986, 'Reversal of cardiac transplant rejection without massive immunosuppression', Circulation, vol. 74, no. 5 II MONOGR. 125.
Michler RE, Smith CR, Drusin RE, Reison DS, Hickey TJ, Lamb J et al. Reversal of cardiac transplant rejection without massive immunosuppression. Circulation. 1986;74(5 II MONOGR. 125).
Michler, Robert E. ; Smith, C. R. ; Drusin, R. E. ; Reison, D. S. ; Hickey, T. J. ; Lamb, J. ; Reemtsma, K. ; Rose, E. A. / Reversal of cardiac transplant rejection without massive immunosuppression. In: Circulation. 1986 ; Vol. 74, No. 5 II MONOGR. 125.
@article{6695ea886ae14417aba8abc6100d7883,
title = "Reversal of cardiac transplant rejection without massive immunosuppression",
abstract = "Although cyclosporine has decreased the severity of acute cardiac transplant rejection, most centers have continued to use high-dose intravenous steroids to treat acute rejection. To minimize the morbidity of antirejection therapy, acute rejection episodes in 37 cardiac transplant recipients were treated prospectively with only a boost of oral prednisone. Cyclospoine was continued at the same maintenance dose while oral prednisone was increased to 100 mg/day for 3 days, then rapidly tapered over 1 week to the maintenance dose. Seventy-six of 85 acute rejection episodes (90{\%}) showed histologic resolution of mycocyte necrosis on repeat biopsy. Three acute rejection episodes (3.5{\%}) resolved only after 'rescue therapy' with intravenous steroid, and an additional three episodes (3.5{\%}) required the combination of intravenous steroid and rabbit antithymocyte globulin to effect resolution. In addition, three acute rejection episodes (3.5{\%}) resulted in graft loss. This was fatal in two patients and one patient underwent successful retransplantation. Oral steroid therapy alone is adequate therapy for most acute rejection episodes in cyclosporine-treated heart transplant recipients, and low infectious morbidity and mortality has been associated with this antirejection protocol.",
author = "Michler, {Robert E.} and Smith, {C. R.} and Drusin, {R. E.} and Reison, {D. S.} and Hickey, {T. J.} and J. Lamb and K. Reemtsma and Rose, {E. A.}",
year = "1986",
language = "English (US)",
volume = "74",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5 II MONOGR. 125",

}

TY - JOUR

T1 - Reversal of cardiac transplant rejection without massive immunosuppression

AU - Michler, Robert E.

AU - Smith, C. R.

AU - Drusin, R. E.

AU - Reison, D. S.

AU - Hickey, T. J.

AU - Lamb, J.

AU - Reemtsma, K.

AU - Rose, E. A.

PY - 1986

Y1 - 1986

N2 - Although cyclosporine has decreased the severity of acute cardiac transplant rejection, most centers have continued to use high-dose intravenous steroids to treat acute rejection. To minimize the morbidity of antirejection therapy, acute rejection episodes in 37 cardiac transplant recipients were treated prospectively with only a boost of oral prednisone. Cyclospoine was continued at the same maintenance dose while oral prednisone was increased to 100 mg/day for 3 days, then rapidly tapered over 1 week to the maintenance dose. Seventy-six of 85 acute rejection episodes (90%) showed histologic resolution of mycocyte necrosis on repeat biopsy. Three acute rejection episodes (3.5%) resolved only after 'rescue therapy' with intravenous steroid, and an additional three episodes (3.5%) required the combination of intravenous steroid and rabbit antithymocyte globulin to effect resolution. In addition, three acute rejection episodes (3.5%) resulted in graft loss. This was fatal in two patients and one patient underwent successful retransplantation. Oral steroid therapy alone is adequate therapy for most acute rejection episodes in cyclosporine-treated heart transplant recipients, and low infectious morbidity and mortality has been associated with this antirejection protocol.

AB - Although cyclosporine has decreased the severity of acute cardiac transplant rejection, most centers have continued to use high-dose intravenous steroids to treat acute rejection. To minimize the morbidity of antirejection therapy, acute rejection episodes in 37 cardiac transplant recipients were treated prospectively with only a boost of oral prednisone. Cyclospoine was continued at the same maintenance dose while oral prednisone was increased to 100 mg/day for 3 days, then rapidly tapered over 1 week to the maintenance dose. Seventy-six of 85 acute rejection episodes (90%) showed histologic resolution of mycocyte necrosis on repeat biopsy. Three acute rejection episodes (3.5%) resolved only after 'rescue therapy' with intravenous steroid, and an additional three episodes (3.5%) required the combination of intravenous steroid and rabbit antithymocyte globulin to effect resolution. In addition, three acute rejection episodes (3.5%) resulted in graft loss. This was fatal in two patients and one patient underwent successful retransplantation. Oral steroid therapy alone is adequate therapy for most acute rejection episodes in cyclosporine-treated heart transplant recipients, and low infectious morbidity and mortality has been associated with this antirejection protocol.

UR - http://www.scopus.com/inward/record.url?scp=0023023187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023023187&partnerID=8YFLogxK

M3 - Article

VL - 74

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5 II MONOGR. 125

ER -